Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists to unravel trust in intellectual disability

NCT ID NCT07434037

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study looks at how people with Down syndrome and Fragile X syndrome decide who to trust. Researchers will use eye-tracking and behavioral tasks to measure how participants read faces, behaviors, and detect deception. The goal is to understand the brain mechanisms behind trust in these groups, which could help improve social support.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could improve understanding of how trust works in people with intellectual disabilities, potentially guiding future social support strategies.
What could go wrong
This is an observational study, not a treatment trial. It is early-stage and may not lead to direct clinical changes. Results may not apply to all individuals with these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Four groups of participants will be included in the study: * Individuals with Down syndrome * Individuals with Fragile X syndrome * Control subjects with typical development matched for chronological age to individuals with intellectual disability (ID) * Control subjects with typical development matched for mental age to individuals with intellectual disability (ID)

Ages

3 to 29 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : Group of Down Syndrom patients * Complete chromosomal trisomy of the 21st chromosome confirmed by karyotype analysis * Aged 13 to 29 (chronological age) * French as their native language * Having signed an informed consent form and/or whose legal guardians/patient representatives have signed the informed consent form * Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system Group of X-Fragile Syndrome * Complete mutation of the FMR1 gene by molecular analysis (more than 200 CGG triplet repeats) * Aged between 13 and 29 (chronological age) * Native French speakers * Having signed an informed consent form and/or whose legal guardians/patient representatives have signed the informed consent form * Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system Group of chronological age-matched control * Aged between 13 and 29 * Native French speakers. * Having signed an informed consent form and/or whose legal guardians/patient representatives have signed the informed consent form * Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system Group of mental age-matched control * Aged between 3 and 9 * Native French speakers. * Whose legal guardians/patient representatives have signed the informed consent form * Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system Exclusion Criteria: Groups of Down Syndrom and X-Fragiles patients * Inability to understand tasks * Significant brain malformation * Uncontrolled epilepsy * Significant hearing impairment * Uncorrected visual impairment * Refusal of the subject and/or legal guardians/representative of the subject to be informed of any abnormalities detected during the neuropsychological assessment. * Subject participating in another interventional study with an exclusion period still ongoing at the time of pre-inclusion. Regarding the neuroimaging (MRI) study: * Having a contraindication to MRI examination (people using a pacemaker or insulin pump, people with metal prostheses or intracerebral clips, people with metal fragments in their eyes, as well as claustrophobic subjects). A comprehensive list of contraindications is provided in Appendix 5. * Inability to perform the MRI without anaesthesia. * Refusal by the subject and/or those exercising parental authority/the subject's representative to be informed of any abnormalities detected during the MRI. Groups of typical development persons (chronological age-matched and mental age-matched) * Known acquired neurological disorders, including epilepsy. * History of head trauma requiring hospitalisation. * Known psychiatric disorders. * Birth complications requiring admission to a neonatal intensive care unit or prematurity of less than 35 weeks. * Ongoing treatment with drugs affecting the central nervous system. * Significant hearing impairment * Uncorrected visual impairment * Repeating a school year * Learning disorders requiring rehabilitation (speech therapy, psychomotor therapy or orthoptics) for more than one year. * Refusal of the subject and/or legal guardians/representative of the subject to be informed of any abnormalities detected during the neuropsychological assessment. * Subject participating in another interventional study with an exclusion period still ongoing at the time of pre-inclusion. Regarding the neuroimaging (MRI) study (only for chronological age-matched group): * Having a contraindication to MRI examination (people using a pacemaker or insulin pump, people with metal prostheses or intracerebral clips, people with metal fragments in their eyes, as well as claustrophobic subjects). A comprehensive list of contraindications is provided in Appendix 5. * Inability to perform the MRI without anaesthesia. * Refusal by the subject and/or those exercising parental authority/the subject's representative to be informed of any abnormalities detected during the MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Down syndrome (trisomy 21) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Reference Center of Rare Disease with Intellectual Disability in Lyon, Woman Mother and Child Hospital, University Hospital of Lyon, Hospices Civils de Lyon

    RECRUITING

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.